Key Players
Competitive Landscape
Consumer preference for inhalers, shaped by prescribers and payers, rests on clinical evidence, ease of use, price and formulary status. Consumer preference for a familiar device keeps patients on the first inhaler prescribed, so first prescriptions carry long-term value.
Originators with triple therapies compete with generic makers selling low-cost combinations and with device specialists that license platforms. Country markets in Europe grow slowly, with the Germany respiratory inhaler devices market projected at a 1.6% CAGR from 2025 to 2035.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| January 2026: Trelegy Ellipta approved in China for asthma. | Uncontrolled asthma. | Single inhaler triple therapy. | New patient groups in East Asia. |
| July 2026: AstraZeneca reports Breztri up 17% at CER. | Triple therapy demand. | Fixed-dose triple combinations. | Step-up maintenance therapy. |
| October 2025: GSK reports low carbon Ventolin data. | Climate rules on propellants. | Low carbon MDIs. | Greener respiratory portfolios. |
| July 2026: GSK reports Trelegy down 7%. | Price pressure. | Generic and payer pressure. | Low-cost device strategies. |
Over the period, originators have leaned on triple therapy and greener devices, so suppliers able to pair proven medicines with easy, low-cost devices will win prescriptions through 2036.
Who leads the dry powder inhaler market?
GSK and AstraZeneca lead branded maintenance therapy, with Chiesi, Novartis and Boehringer Ingelheim strong in Europe. Among generic makers, Teva and Cipla lead powder inhalers.
Which companies have documented positions?
GSK, AstraZeneca and Chiesi hold clear positions backed by approved triple and dual therapies and global reach. For generic powder combinations, Teva, Cipla and Mylan hold established positions.
What should buyers evaluate before approving a supplier?
Payers and hospitals review clinical evidence, device ease of use and price first, as these drive outcomes and cost. Supply reliability, patient training support and environmental footprint also shape approval.
How is competition expected to change through 2036?
Originators will rely on triple therapies and new indications. Generic makers are likely to gain volume, and device specialists will compete on platforms that cut cost and improve technique.
Representative Company Overview
| Company | Positioning | Recent development |
|---|---|---|
| GlaxoSmithKline | Originator respiratory company with Ellipta platform | January 2026: Trelegy Ellipta approved in China for asthma. |
| AstraZeneca | Originator respiratory and immunology company | July 2026: Breztri up 17% at CER in the first half. |
| Cipla | Generic and regional respiratory maker | Profiled for low-cost inhalers. |
| Hovione | Inhalation formulation and device specialist | Profiled for dry powder formulation services. |
Research Methodology
The companies included in the report represent current market structure and do not indicate a market-share ranking. Company profiles draw on product portfolios, regional presence and recent strategic moves.
